Roche Holding AG News
-
Novartis AG plans to ramp up its research in Alzheimer’s disease, a potential $20 billion market lacking a major contender and littered with three high-profile drug failures in the past year alone.
-
Swiss billionaires Ernesto Bertarelli and Hansjoerg Wyss have acquired Merck KGaA’s Geneva headquarters to turn it into a biotechnology campus.
-
Two drugs from Bristol-Myers Squibb Co. shrank tumors in as many as half of patients with advanced melanoma, according to early research that may pave the way for cocktails that trigger the immune system to destroy cancer.
-
Roche Holding AG’s experimental leukemia drug shrank tumors in more patients when added to chemotherapy, according to study results that may aid the company in expanding its line of blood-cancer treatments.
-
Roche Holding AG, the world’s biggest maker of cancer drugs, won U.S. approval to sell a gene mutation test that can help doctors pinpoint patients’ likelihood to respond to a popular treatment for lung cancer.
-
Swiss stocks rose for a second day, extending the benchmark Swiss Market Index’s highest level in more than five years.
-
Merck & Co., Bristol-Myers Squibb Co. and Roche Holding AG have opened a new front against cancer with the next generation of experimental drugs that use the human immune system to seek and destroy tumor cells.
-
Bristol-Myers Squibb Co. sued Roche Holding AG’s Genentech unit seeking a court order that it doesn’t infringe patents used to make treatments for cancer and autoimmune diseases.
-
Bristol-Myers Squibb Co. sued Roche Holding AG’s Genentech unit seeking a ruling it doesn’t infringe patents used to make treatments for cancer and autoimmune diseases.
-
Want Viagra without the inconvenience and potential embarrassment of the pharmacy line?
|
|
Most Popular on Bloomberg
|
| |
Rate this Page